Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
SeaStar Medical Holding Corporation(ICU)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ICU
10/02/2026: ICU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
SeaStar Medical Holding Corporation is a development-stage medical technology company focusing on extracorporeal blood purification devices designed to treat hyperinflammation in critically ill patients. Its primary strength lies in its proprietary Selective Cytopheretic Device (SCD) platform, which addresses high-need areas like acute kidney injury. The investment story revolves around achieving successful clinical milestones and regulatory approvals for its devices. Key risks include significant financial losses, ongoing dilution from capital raises, and intense competition from established global medical device providers. The company is best suited for high-risk, growth-oriented investors who should closely monitor clinical trial results and FDA regulatory updates for any material developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to regulatory success, but carries extreme binary risk. |
| Momentum investor | Weak fit | The stock often exhibits high volatility without consistent trend-based momentum indicators. |
| Value investor | Weak fit | The company lacks current earnings or tangible assets to support a traditional value-based valuation. |
| Dividend investor | Weak fit | The company is a cash-burning developer and does not provide income. |
| Low-risk investor | Weak fit | The company is high-risk due to its clinical development stage and financial volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical trial news or financing events. |
| Valuation risk | High | Valuation is speculative as it depends on uncertain future regulatory approvals and market adoption. |
| Competition risk (large medical device peers) | High | Established players have massive resources and distribution networks that are difficult to challenge. |
| Business quality | Medium / high | As a development-stage company, the business is pre-revenue and lacks long-term operational history. |
| Dividend income | Low / none | The company does not pay dividends and is unlikely to do so in the near future. |
| Execution risk | High | Successful commercialization depends on complex clinical trials and regulatory navigation. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -48.94% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.67M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 60.7K shares | Beta -1.03 | 52 Weeks Range 2.07 - 7.35 | Updated Date 10/02/2026 |
52 Weeks Range 2.07 - 7.35 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Devices | Selective Cytopheretic Device (SCD) for blood purification. | The company makes money (or intends to) by selling specialized devices to hospitals to treat critically ill patients. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8.77M | Price to Sales(TTM) 12.07 |
Enterprise Value 8.77M | Price to Sales(TTM) 12.07 | ||
Enterprise Value to Revenue 5.12 | Enterprise Value to EBITDA -8.13 | Shares Outstanding 4.41M | Shares Floating 4.36M |
Shares Outstanding 4.41M | Shares Floating 4.36M | ||
Percent Insiders 11.62 | Percent Institutions 7.62 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About SeaStar Medical Holding Corporation
Exchange NASDAQ | Headquarters Denver, CO, United States | ||
IPO Launch date 2022-10-28 | CEO, Treasurer, President & Executive Director Mr. Eric Schlorff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://seastarmedical.com |
Full time employees 18 | Website https://seastarmedical.com | ||
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.